Next Article in Journal
Neural Hyperexcitability in Autism Spectrum Disorders
Previous Article in Journal
An Overview of Recent Findings on Social Anxiety Disorder in Adolescents and Young Adults at Clinical High Risk for Psychosis
Previous Article in Special Issue
Cognitive Changes in the Spinocerebellar Ataxias Due to Expanded Polyglutamine Tracts: A Survey of the Literature
Article Menu

Export Article

Open AccessReview
Brain Sci. 2017, 7(10), 128; doi:10.3390/brainsci7100128

Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases

Department of Neurotherapeutics, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan
*
Authors to whom correspondence should be addressed.
Received: 30 August 2017 / Revised: 30 September 2017 / Accepted: 10 October 2017 / Published: 11 October 2017
(This article belongs to the Special Issue Polyglutamine (PolyQ) Disorders)
View Full-Text   |   Download PDF [578 KB, uploaded 16 October 2017]   |  

Abstract

The polyglutamine (polyQ) diseases, such as Huntington’s disease and several types of spinocerebellar ataxias, are a group of inherited neurodegenerative diseases that are caused by an abnormal expansion of the polyQ tract in disease-causative proteins. Proteins with an abnormally expanded polyQ stretch undergo a conformational transition to β-sheet rich structure, which assemble into insoluble aggregates with β-sheet rich amyloid fibrillar structures and accumulate as inclusion bodies in neurons, eventually leading to neurodegeneration. Since misfolding and aggregation of the expanded polyQ proteins are the most upstream event in the most common pathogenic cascade of the polyQ diseases, they are proposed to be one of the most ideal targets for development of disease-modifying therapies for polyQ diseases. In this review, we summarize the current understanding of the molecular pathogenic mechanisms of the polyQ diseases, and introduce therapeutic approaches targeting misfolding and aggregation of the expanded polyQ proteins, which are not only effective on a wide spectrum of polyQ diseases, but also broadly correct the functional abnormalities of multiple downstream cellular processes affected in the aggregation process of polyQ proteins. We hope that in the near future, effective therapies are developed, to bring hope to many patients suffering from currently intractable polyQ diseases. View Full-Text
Keywords: polyglutamine diseases; Huntington’s disease; conformational change; aggregation; misfolding; β-sheet monomer; therapeutic target; QBP1; molecular chaperone polyglutamine diseases; Huntington’s disease; conformational change; aggregation; misfolding; β-sheet monomer; therapeutic target; QBP1; molecular chaperone
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Takeuchi, T.; Nagai, Y. Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases. Brain Sci. 2017, 7, 128.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Brain Sci. EISSN 2076-3425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top